Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2016 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to check the transcript. Management (Art Przybyl and Steve Carey) discuss their business. They talk about product launches, acquisitions, Corticotropin project, guidance, etc. They mention "we have established long-term contractual relationships with the four folks or entities that comprise better than 95% percent of all of the scripts in the country for our type of products that we market." That is about customers, but they don't describe those customers' own growth or scaling. They talk about their own product launches, acquisitions, and internal efforts. They mention "we terminated our distribution agreement for Hydroxyprogesterone Caproate" and "we received cash and an undisclosed NDA." They talk about their own pipeline, R&D, etc. They do not narrate what their customers or partners are doing in terms of their own expansion. They mention "our partner IDT out of Australia" but only in passing about product launches. They don't describe IDT's own trajectory. They talk about Corticotropin project but that's their own project. They don't describe counterparties' growth as the driver. The forward account is about their own actions: launching products, acquiring assets, investing in R&D, etc. So the answer is NO. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.